RO5126766
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for RO5126766, covering 2016-11-02 to 2024-07-10. Get the full timeline:
Most recent: Clinical Trial Update: RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer [Phase 1]